FOCUS on new drug approvals. On February 24th the FDA granted approval to Encorafenib (Braftovi, Array Biopharma, a subsidiary of Pfizer) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation as detected by an FDA-authorized test. Encorafenib had received accelerated approval in combination with cetuximab and mFOLFOX6 for the same indication in 2024. Encorafenib (LGX818) is a selective inhibitor of B-Raf V600E mutant.
Focus Biomolecules offers Encorafenib for research applications. Contact us for more information.
